Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial

Importance Mailed fecal immunochemical test (FIT) outreach is more effective than colonoscopy outreach for increasing 1-time colorectal cancer (CRC) screening, but long-term effectiveness may need repeat testing and timely follow-up for abnormal results. Objective Compare the effectiveness of FIT outreach and colonoscopy outreach to increase completion of the CRC screening process (screening initiation and follow-up) within 3 years. Design, Setting, and Participants Pragmatic randomized clinical trial from March 2013 to July 2016 among 5999 participants aged 50 to 64 years who were receiving primary care in Parkland Health and Hospital System and were not up to date with CRC screenings. Interventions Random assignment to mailed FIT outreach (n = 2400), mailed colonoscopy outreach (n = 2400), or usual care with clinic-based screening (n = 1199). Outreach included processes to promote repeat annual testing for individuals in the FIT outreach group with normal results and completion of diagnostic and screening colonoscopy for those with an abnormal FIT result or assigned to colonoscopy outreach. Main Outcomes and Measures Primary outcome was screening process completion, defined as adherence to colonoscopy completion, annual testing for a normal FIT result, diagnostic colonoscopy for an abnormal FIT result, or treatment evaluation if CRC was detected. Secondary outcomes included detection of any adenoma or advanced neoplasia (including CRC) and screening-related harms (including bleeding or perforation). Results All 5999 participants (median age, 56 years; women, 61.9%) were included in the intention-to-screen analyses. Screening process completion was 38.4% in the colonoscopy outreach group, 28.0% in the FIT outreach group, and 10.7% in the usual care group. Compared with the usual care group, between-group differences for completion were higher for both outreach groups (27.7% [95% CI, 25.1% to 30.4%] for the colonoscopy outreach group; 17.3% [95% CI, 14.8% to 19.8%] for FIT outreach group), and highest in the colonoscopy outreach group (10.4% [95% CI, 7.8% to 13.1%] for the colonoscopy outreach group vs FIT outreach group; P < .001 for all comparisons). Compared with usual care, the between-group differences in adenoma and advanced neoplasia detection rates were higher for both outreach groups (colonoscopy outreach group: 10.3% [95% CI, 9.5% to 12.1%] for adenoma and 3.1% [95% CI, 2.0% to 4.1%] for advanced neoplasia, P < .001 for both comparisons; FIT outreach group: 1.3% [95% CI, −0.1% to 2.8%] for adenoma and 0.7% [95% CI, −0.2% to 1.6%] for advanced neoplasia, P < .08 and P < .13, respectively), and highest in the colonoscopy outreach group (colonoscopy outreach group vs FIT outreach group: 9.0% [95% CI, 7.3% to 10.7%] for adenoma and 2.4% [95% CI, 1.3% to 3.3%] for advanced neoplasia, P < .001 for both comparisons). There were no screening-related harms in any groups. Conclusions and Relevance Among persons aged 50 to 64 years receiving primary care at a safety-net institution, mailed outreach invitations offering FIT or colonoscopy compared with usual care increased the proportion completing CRC screening process within 3 years. The rate of screening process completion was higher with colonoscopy than FIT outreach. Trial Registration clinicaltrials.gov Identifier: NCT01710215

[1]  T. Thompson,et al.  Cancer Screening Test Use — United States, 2015 , 2017, MMWR. Morbidity and mortality weekly report.

[2]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[3]  M. Pignone,et al.  Multilevel predictors of colorectal cancer testing modality among publicly and privately insured people turning 50 , 2016, Preventive medicine reports.

[4]  M. Phipps,et al.  Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. , 2016, JAMA.

[5]  Jasmin A. Tiro,et al.  Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety‐net health system , 2016, Cancer.

[6]  E. Halm,et al.  Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems , 2016, Cancer Epidemiology, Biomarkers and Prevention.

[7]  Alison R. T. Brenner,et al.  Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years , 2016, The American Journal of Gastroenterology.

[8]  E. Halm,et al.  Predictors of guideline concordance for surveillance colonoscopy recommendations in patients at a safety-net health system , 2015, Cancer Causes & Control.

[9]  A. Jemal,et al.  Elimination of cost‐sharing and receipt of screening for colorectal and breast cancer , 2015, Cancer.

[10]  Chyke A Doubeni,et al.  How Can We Boost Colorectal and Hepatocellular Cancer Screening Among Underserved Populations? , 2015, Current Gastroenterology Reports.

[11]  P. Bossuyt,et al.  Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening. , 2015, Cancer epidemiology.

[12]  Fernando A. Wilson,et al.  Cost-Effectiveness Analysis of a Colonoscopy Screening Navigator Program Designed for Hispanic Men , 2015, Journal of Cancer Education.

[13]  Yinghui Xu,et al.  Comparison of patient preferences for fecal immunochemical test or colonoscopy using the analytic hierarchy process , 2015, BMC Health Services Research.

[14]  S. Vernon,et al.  Results of Nurse Navigator Follow-up After Positive Colorectal Cancer Screening Test: A Randomized Trial , 2014, The Journal of the American Board of Family Medicine.

[15]  M. Wolf,et al.  Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial. , 2014, JAMA internal medicine.

[16]  Yingye Zheng,et al.  The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[17]  D. Ransohoff,et al.  Multitarget stool DNA testing for colorectal-cancer screening. , 2014, The New England journal of medicine.

[18]  B. Farham Quantification of harms in cancer screening trials: Literature review , 2013 .

[19]  Jasmin A. Tiro,et al.  Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. , 2013, JAMA Internal Medicine.

[20]  J. Le Breton,et al.  Colorectal cancer screening: factors associated with colonoscopy after a positive faecal occult blood test , 2013, British Journal of Cancer.

[21]  C. Messina,et al.  Clinical case management and navigation for colonoscopy screening in an academic medical center , 2013, Cancer.

[22]  B. Denis,et al.  Harms of colonoscopy in a colorectal cancer screening programme with faecal occult blood test: a population-based cohort study. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[23]  M. Schluchter,et al.  Use of colonoscopy for polyp surveillance in Medicare beneficiaries , 2013, Cancer.

[24]  J. Feinglass,et al.  Adherence to Repeat Fecal Occult Blood Testing in an Urban Community Health Center Network , 2013, Journal of Community Health.

[25]  E. Emanuel,et al.  Shared decision making to improve care and reduce costs. , 2013, The New England journal of medicine.

[26]  L. K. Bartholomew,et al.  Preferences for colorectal cancer screening tests and screening test use in a large multispecialty primary care practice , 2012, Cancer.

[27]  Angela Fagerlin,et al.  Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. , 2012, Archives of internal medicine.

[28]  M. Barry,et al.  Shared decision making--pinnacle of patient-centered care. , 2012, The New England journal of medicine.

[29]  Á. Lanas,et al.  Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. , 2012, The New England journal of medicine.

[30]  J. Habbema,et al.  Fecal occult blood testing when colonoscopy capacity is limited. , 2011, Journal of the National Cancer Institute.

[31]  B. Leggett,et al.  Repeat participation in colorectal cancer screening utilizing fecal occult blood testing: A community‐based project in a rural setting , 2010, Journal of gastroenterology and hepatology.

[32]  Joann G Elmore,et al.  Longitudinal Adherence With Fecal Occult Blood Test Screening in Community Practice , 2010, The Annals of Family Medicine.

[33]  H. Brenner,et al.  Protection from colorectal cancer after colonoscopy: Population-based case-control study , 2010 .

[34]  S. Ryu,et al.  Comparison of Guaiac-Based and Quantitative Immunochemical Fecal Occult Blood Testing in a Population at Average Risk Undergoing Colorectal Cancer Screening , 2010, The American Journal of Gastroenterology.

[35]  D. Jonas,et al.  Systematic Review: Enhancing the Use and Quality of Colorectal Cancer Screening , 2010, Annals of Internal Medicine.

[36]  Cancer,et al.  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial , 2010, The Lancet.

[37]  D. Comaneshter,et al.  Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use , 2010, Cancer.

[38]  S. Taplin,et al.  Interfaces across the cancer continuum offer opportunities to improve the process of care. , 2010, Journal of the National Cancer Institute. Monographs.

[39]  B. Balluff,et al.  Performance of Epigenetic Markers SEPT9 and ALX4 in Plasma for Detection of Colorectal Precancerous Lesions , 2010, PloS one.

[40]  B. Hemmelgarn,et al.  Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  L. Seeff,et al.  The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. , 2009, Health economics.

[42]  Christian Pilarsky,et al.  Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. , 2009, Clinical chemistry.

[43]  Sun Hee Rim,et al.  Colorectal cancer incidence in the United States, 1999‐2004 , 2009, Cancer.

[44]  Hardeep Singh,et al.  Using a Multifaceted Approach to Improve the Follow-Up of Positive Fecal Occult Blood Test Results , 2009, The American Journal of Gastroenterology.

[45]  Samir Gupta Will test-specific adherence predict the best colorectal cancer screening strategy? , 2009, Annals of internal medicine.

[46]  Sandhya K. Rao,et al.  Challenges in the Management of Positive Fecal Occult Blood Tests , 2009, Journal of General Internal Medicine.

[47]  L. Rabeneck,et al.  Association of Colonoscopy and Death From Colorectal Cancer , 2009, Annals of Internal Medicine.

[48]  Rinku Sutradhar,et al.  Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. , 2008, Gastroenterology.

[49]  C. Pilarsky,et al.  Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay , 2008, PloS one.

[50]  Amy B. Knudsen,et al.  Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[51]  D. Sargent,et al.  Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia , 2008, Annals of Internal Medicine.

[52]  E. Feuer,et al.  Improvement in the Diagnostic Evaluation of a Positive Fecal Occult Blood Test in an Integrated Health Care Organization , 2008, Medical care.

[53]  R. Coates,et al.  Trends in colorectal cancer screening disparities in people aged 50-64 years, 2000-2005. , 2008, American journal of preventive medicine.

[54]  T. Sensky,et al.  Systematic Review of the Effects of Shared Decision-Making on Patient Satisfaction, Treatment Adherence and Health Status , 2008, Psychotherapy and Psychosomatics.

[55]  E. Emanuel,et al.  Quality-improvement research and informed consent. , 2008, The New England journal of medicine.

[56]  Terry Hyslop,et al.  A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening , 2007, Cancer.

[57]  L. Bisanti,et al.  Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. , 2007, Gastroenterology.

[58]  M. Leshno,et al.  A Quantitative Immunochemical Fecal Occult Blood Test for Colorectal Neoplasia , 2007, Annals of Internal Medicine.

[59]  A. Spigelman A comparison of colorectal neoplasia screening tests: a multicentre community‐based study of the impact of consumer choice , 2006, The Medical journal of Australia.

[60]  D. Fisher,et al.  Barriers to Full Colon Evaluation for a Positive Fecal Occult Blood Test , 2006, Cancer Epidemiology Biomarkers & Prevention.

[61]  Lisa V Rubenstein,et al.  Measuring the Quality of Colorectal Cancer Screening: The Importance of Follow-Up , 2006, Diseases of the colon and rectum.

[62]  Donald M Berwick,et al.  All-or-none measurement raises the bar on performance. , 2006, JAMA.

[63]  A. Sonnenberg,et al.  Comparing risks and benefits of colorectal cancer screening in elderly patients. , 2005, Gastroenterology.

[64]  A. Schatzkin,et al.  Colonoscopic screening of average-risk women for colorectal neoplasia. , 2005, The New England journal of medicine.

[65]  D. Ransohoff,et al.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.

[66]  L. Seeff,et al.  Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? , 2004, Gastroenterology.

[67]  J. Faivre,et al.  Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. , 2004, Gastroenterology.

[68]  Timothy R Church,et al.  A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening. , 2004, Journal of the National Cancer Institute.

[69]  Terry Hyslop,et al.  Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. , 2004, Preventive medicine.

[70]  M. Cowen,et al.  The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. , 2003, Archives of internal medicine.

[71]  J. Selby,et al.  Complications of screening flexible sigmoidoscopy. , 2002, Gastroenterology.

[72]  Margaret Maglione,et al.  Interventions That Increase Use of Adult Immunization and Cancer Screening Services , 2002, Annals of Internal Medicine.

[73]  J. Scholefield,et al.  Psychiatric morbidity and screening for colorectal cancer , 2002, Journal of medical screening.

[74]  Amnon Sonnenberg,et al.  Cost-effectiveness of a single colonoscopy in screening for colorectal cancer. , 2002, Archives of internal medicine.

[75]  D. Lieberman,et al.  One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. , 2001, The New England journal of medicine.

[76]  D. Lieberman,et al.  Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. , 2000, The New England journal of medicine.

[77]  S. Moss,et al.  The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer , 1999, Gut.

[78]  D. Torgerson,et al.  Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. , 1999, QJM : monthly journal of the Association of Physicians.

[79]  J. Olsen,et al.  Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.

[80]  A. Sonnenberg,et al.  Prevention of Colorectal Cancer by Flexible Endoscopy and Polypectomy: A Case-Control Study of 32 702 Veterans , 1995, Annals of Internal Medicine.

[81]  G. Friedman,et al.  A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. , 1992, The New England journal of medicine.

[82]  C. Jepson,et al.  Behavioral Interventions to Increase Adherence in Colorectal Cancer Screening , 1991, Medical care.

[83]  T. Marteau,et al.  Psychological costs of screening. , 1989, BMJ.

[84]  T. Taguchi,et al.  [Occult blood screening for colorectal cancer]. , 1986, Gan to kagaku ryoho. Cancer & chemotherapy.

[85]  Jasmin A. Tiro,et al.  Reasons for Lack of Diagnostic Colonoscopy After Positive Result on Fecal Immunochemical Test in a Safety-Net Health System. , 2017, The American journal of medicine.

[86]  J. V Schönfeld [Colonoscopy versus fecal immunochemical testing in colorectal cancer screening]. , 2013, Zeitschrift fur Gastroenterologie.

[87]  R. Hayes,et al.  Utilization of surveillance colonoscopy in community practice. , 2010, Gastroenterology.

[88]  J. Yee,et al.  Accuracy of ct colonography for detection of large adenomas and cancers , 2009 .

[89]  L. Rabeneck,et al.  Endoscopic follow-up of positive fecal occult blood testing in the Ontario FOBT Project. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[90]  M. Manos,et al.  A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[91]  D. Rex,et al.  Distal colonic hyperplastic polyps do not predict proximal adenomas in asymptomatic average-risk subjects. , 1992, Gastroenterology.

[92]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.